Strides Pharma Science

Strides Pharma Science EBIT per osake

EBIT per osake yhtiöstä Strides Pharma Science (STAR.NS) 16.10.2026 päivämäärällä on 66,65 INR. Edellisenä vuonna EBIT per osake oli 40,79 INR — muutos 63,39 % (korkeampi).

EBIT per osake

66,65INR

YoY

63,39%

Viimeksi päivitetty:

EBIT per osake yhtiöstä Strides Pharma Science on 2025 66,65 INR. EBIT per osake yhtiöstä Strides Pharma Science oli 2024 40,79 INR. Se laskee 63,39% korkeampi edelliseen vuoteen verrattuna.

Strides Pharma Science EBIT per osake historia

  • 3 vuotta

  • 10 vuotta

  • 25 vuotta

  • Maksimi

EBIT per osake
Päivämäärä
EBIT per osake
1.1.2022
−26,08 INR
1.1.2023
16,06 INR
1.1.2024
40,79 INR
1.1.2025
66,65 INR
1.1.2026 (e)
92,36 INR
1.1.2027 (e)
107,82 INR
1.1.2028 (e)
141,03 INR
1.1.2029 (e)
142,91 INR
Strides Pharma Science EBIT per osake historia
VUOSIEBIT per osakeYoY
est142,91INR+1,33%
est141,03INR+30,80%
est107,82INR+16,74%
est92,36INR+38,57%
66,65INR+63,39%
40,79INR+154,07%
16,06INR−161,57%
−26,08INR−154,23%
48,09INR+15,78%
41,53INR+153,08%
16,41INR−43,02%
28,80INR−36,35%
45,24INR+29,36%
34,98INR+13,37%
30,85INR−8,81%
33,83INR+66,61%
20,31INR−72,42%
73,61INR+24,68%
59,04INR+121,20%
26,69INR+356,33%
5,85INR−135,30%
−16,57INR−175,32%
22,00INR−1,04%
22,23INR—

Hae nämä tiedot Eulerpool API:n kautta

100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia

Strides Pharma Science Osakeanalyysi

Mitä Strides Pharma Science tekee? Strides Pharma Science Ltd, trading under the ticker symbol STAR.NS and identified by ISIN INE939A01011, is a prominent entity within the Indian healthcare sector, specifically operating in the pharmaceuticals industry. Headquartered in Bangalore, Karnataka, the company has established itself as a significant player in the global market for generic and bio-pharmaceutical products. Strides Pharma Science Ltd went public on February 3, 2000, marking a pivotal moment in its corporate history and allowing it to expand its operational footprint. The organization currently employs approximately 2,850 full-time staff members who are dedicated to the development, manufacture, and distribution of its diverse product portfolio. The company’s business activities are primarily divided into two main segments: Pharmaceutical and Bio-pharmaceutical. This structural division allows the firm to focus on both traditional generic drugs and more complex biological therapeutics, ensuring a balanced approach to meeting varied market demands. Geographically, Strides Pharma Science Ltd has a broad international presence, serving markets across Africa, Australia, Asia excluding India, North America, Europe, India, and other regions. This extensive reach is supported by a robust manufacturing infrastructure comprising eight distinct units. These facilities are strategically located to optimize supply chain efficiency and regulatory compliance. In India, the company operates two manufacturing sites in Bengaluru, along with additional facilities in Puducherry and Chennai. Beyond its domestic operations, Strides maintains manufacturing capabilities in Singapore, Milan, Italy, Florida, United States, and Nairobi, Kenya. This global network enables the company to produce a wide array of dosage forms, including liquids, creams, ointments, soft gels, sachets, tablets, and modified-release formats. Notably, the company is also engaged in the specialized manufacturing of soft gelatin capsules. The firm’s product development strategy emphasizes intellectual property-led niche products, distinguishing it from competitors who may focus solely on standard generics. The therapeutic areas covered by Strides Pharma Science Ltd are extensive, with a strong emphasis on drugs for anti-retroviral, anti-malarial, anti-tuberculosis, and hepatitis treatments, as well as other infectious diseases. This focus on high-impact therapeutic segments underscores the company’s commitment to addressing critical global health challenges. By combining a strong manufacturing base with a diverse product range and a global distribution network, Strides Pharma Science Ltd continues to play a vital role in the pharmaceutical landscape, providing essential medicines to patients worldwide while maintaining its position as a key player in the Indian stock market. Strides Pharma Science on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset Strides Pharma Science osakkeesta

Yhtiön Strides Pharma Science EBIT per osake on 66,65 INR vuonna 2025.

EBIT per osake yhtiöstä Strides Pharma Science muuttui arvosta 40,79 INR arvoon 66,65 INR, mikä edustaa 63,39 % muutosta. Arvo on korkeampi kuin edellisenä vuonna.

Eurpoolissa voit löytää EBIT per osake Strides Pharma Science:n täydellisen historiallisen kehityksen vuodesta 2006 lähtien – vuotuisten arvojen, kaavioiden ja yksityiskohtaisen analyysin kanssa.

EBIT per osake mittaa operatiivisen voiton, joka on kohdistettu kullekin ulkona olevalle osakkeelle.

Hae nämä tiedot Eulerpool API:n kautta

100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia

Tuloslaskelma — Strides Pharma Science

Kaikki tunnusluvut — Strides Pharma Science